Interleukin-8, CXCL1, and MicroRNA miR-146a responses to probiotic Escherichia coli Nissle 1917 and enteropathogenic E. coli in human intestinal epithelial T84 and monocytic THP-1 cells after apical or basolateral infection

Infection and Immunity

Volumn 84, Issue 9, 2016, Pages 2482-2492

  Sabharwal, Harshana ^a   Cichon, Christoph ^a   Ölschläger, Tobias A ^b   Sonnenborn, Ulrich ^c   Alexander Schmidt, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Ardeypharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; FLAGELLIN; INTERLEUKIN 8; MICRORNA 146A; CXCL1 PROTEIN, HUMAN; ESCHERICHIA COLI PROTEIN; IL8 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MIRN146 MICRORNA, HUMAN; PROBIOTIC AGENT;

ARTICLE; BACTERIAL FLAGELLUM; BACTERIAL STRAIN; BACTERIUM MUTANT; CELL INTERACTION; CELL LINE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; HOST CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTESTINE EPITHELIUM CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T84 CELL LINE; THP 1 CELL LINE; TYPE III SECRETION SYSTEM; WILD TYPE; EPITHELIUM CELL; FLAGELLUM; INTESTINE; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY;

CELL LINE; CHEMOKINE CXCL1; ENTEROPATHOGENIC ESCHERICHIA COLI; EPITHELIAL CELLS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLAGELLA; FLAGELLIN; HUMANS; INTERLEUKIN-8; INTESTINAL MUCOSA; INTESTINES; MICRORNAS; MONOCYTES; NF-KAPPA B; PROBIOTICS;

EID: 84984794077     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00402-16     Document Type: Article

References (71)

1. Belkaid Y, Hand TW. 2014. Role of microbiota in immunity and inflammation. Cell 157: 121-141. http://dx.doi.org/10.1016/j.cell.2014.03.011.
2. Hooper LV, Gordon JI. 2001. Commensal host-bacterial relationships in the gut. Science 292: 1115-1118. http://dx.doi.org/10.1126/science.1058709.
3. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. 2011. Bacteria and host interactions in the gut epithelial barrier. Nat Chem Biol 8: 36-45. http://dx.doi.org/10.1038/nchembio.741.
4. Winter SE, Lopez CA, Bäumler A. 2013. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep 14: 319-327. http://dx.doi.org/10.1038/embor.2013.27.
5. Lebeer S, Vanderleyden J, De Keersmaecker SC. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8: 171-184. http://dx.doi.org/10.1038/nrmicro2297.
6. Kravchenko VV, Kaufmann GF. 2013. Bacterial inhibition of inflammatory responses via TLR-independent mechanisms. Cell Microbiol 15: 527-536. http://dx.doi.org/10.1111/cmi.12109.
7. He X, Jing Z, Cheng G. 2014. MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int 2014: 945169. http://dx.doi.org/10.1155/2014/945169.
8. Zhou R, O'Hara SP, Chen X-M. 2011. MicroRNA regulation of innate immune responses in epithelial cells. Cell Mol Immunol 8: 371-379. http://dx.doi.org/10.1038/cmi.2011.19.
9. Eulalio A, Schulte L, Vogel J. 2012. The mammalian microRNA response to bacterial infections. RNA Biol 9: 742-750. http://dx.doi.org/10.4161/rna.20018.
10. Flór TB, Blom B. 2016. Pathogens use and abuse microRNAs to deceive the immune system. Int J Mol Sci 17: E538. http://dx.doi.org/10.3390/ijms17040538.
11. Puleston J, Cooper M, Murch S, Bid K, Makh S, Ashwood P, Bingham AH, Green H, Moss P, Dhillon A, Morris R, Strobel S, Gelinas R, Pounder RE, Platt A. 2005. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment Pharmacol Ther 21: 109-120. http://dx.doi.org/10.1111/j.1365-2036.2004.02262.x.
12. Egesten A, Eliasson M, Olin AI, Erjefält JS, Bjartell A, Sangfeldt P, Carlson M. 2007. The proinflammatory CXC-chemokine GRO-/CXCL1 and MIG(CXCL9) are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis 22: 1421-1427. http://dx.doi.org/10.1007/s00384-007-0370-3.
13. Atreya R, Neurath MF. 2010. Chemokines in inflammatory bowel disease. Dig Dis 28: 386-394. http://dx.doi.org/10.1159/000320392.
14. Schaefer JS, Attumi T, Opekun AR, Abraham B, Hou J, Shelby H, Graham DY, Streckfus C, Klein JR. 2015. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis. BMC Immunol 16: 5. http://dx.doi.org/10.1186/s12865-015-0069-0.
15. Dalal SR, Kwon JH. 2010. The role of microRNA in inflammatory bowel disease. Gastroenterol Hepatol 6: 714-722.
16. Van der Goten J, Vanhove W, Lemaire K, Van Lommel L, Machiels K, Wollants WE, De Preter V, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I. 2014. Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. PLoS One 9: e116117. http://dx.doi.org/10.1371/journal.pone.0116117.
17. Quinn SR, O'Neill LA. 2011. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 23: 421-425. http://dx.doi.org/10.1093/intimm/dxr034.
18. Nahid MA, Satoh M, Chan EK. 2011. MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol 8: 388-403. http://dx.doi.org/10.1038/cmi.2011.26.
19. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, Sun G, Tay J, Linsley PS, Baltimore D. 2011. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208: 1189-1201. http://dx.doi.org/10.1084/jem.20101823.
20. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. 2011. NF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A 108: 9184-9189. http://dx.doi.org/10.1073/pnas.1105398108.
21. FAO. 2006. Probiotics in food: health and nutritional properties and guidelines for evaluation. FAO food and nutrition paper 85. FAO, Rome, Italy.
22. Vieira AT, Teixeira MM, Martins FS. 2013. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol 4: 445. http://dx.doi.org/10.3389/fimmu.2013.00445.
23. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. 2009. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15: 300-310. http://dx.doi.org/10.1002/ibd.20602.
24. Sonnenborn U, Schulze J. 2009. The non-pathogenic Escherichia coli Nissle 1917-features of a versatile probiotic. Microb Ecol Health Dis 21: 122-158. http://dx.doi.org/10.3109/08910600903444267.
25. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. 2003. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 18: 45-56.
26. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A. 2006. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2-and Toll-like receptor 4-dependent pathways. Infect Immun 74: 4075-4082. http://dx.doi.org/10.1128/IAI.01449-05.
27. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, Wolff C, Schulze J. 2007. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 166: 311-318. http://dx.doi.org/10.1007/s00431-007-0419-x.
28. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. 2007. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9: 804-816. http://dx.doi.org/10.1111/j.1462-5822.2006.00836.x.
29. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. 2007. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2: e1308. http://dx.doi.org/10.1371/journal.pone.0001308.
30. Rembacken BJ, Snelling Am Hawkey PM, Chalmers DM, Axon ATR. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 354: 635-639. http://dx.doi.org/10.1016/S0140-6736(98)06343-0.
31. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623. http://dx.doi.org/10.1136/gut.2003.037747.
32. Schultz M. 2008. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018. http://dx.doi.org/10.1002/ibd.20377.
33. Kaper JB, Nataro JP, Mobley HL. 2004. Pathogenic Escherichia coli. Nat Rev Microbiol 2: 123-140. http://dx.doi.org/10.1038/nrmicro818.
34. Wong AR, Pearson JS, Bright MD, Munera D, Robinson KS, Lee SF, Frankel G, Hartland EL. 2011. Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Mol Microbiol 80: 1420-1438. http://dx.doi.org/10.1111/j.1365-2958.2011.07661.x.
35. Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vázquez A, Barba J, Ibarra JA, O'Donnell P, Metalnikov P, Ashman K, Lee S, Goode D, Pawson T, Finlay BB. 2004. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci U S A 101: 3597-3602. http://dx.doi.org/10.1073/pnas.0400326101.
36. Schmidt MA. 2010. LEEways: tales of EPEC, ATEC and EHEC. Cell Microbiol 12: 1544-1552. http://dx.doi.org/10.1111/j.1462-5822.2010.01518.x.
37. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. 2013. Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26: 822-880. http://dx.doi.org/10.1128/CMR.00022-13.
38. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. 2007. Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 75: 2399-2407. http://dx.doi.org/10.1128/IAI.01563-06.
39. Erdelt S. 2015. Analysis of the interaction mechanisms of the probiotic E. coli Nissle 1917 with intestinal mucin/mucin 2. B.S. thesis. University of Würzburg, Würzburg, Germany.
40. Donnenberg MS, Calderwood SB, Donohue-Rolfe A, Keusch GT, Kaper JB. 1990. Construction and analysis of TnphoA mutants of enteropathogenic Escherichia coli unable to invade HEp-2 cells. Infect Immun 58: 1565-1571.
41. Donnenberg MS, Yu J, Kaper JB. 1993. A second chromosomal gene necessary for intimate attachment of enteropathogenic Escherichia coli to epithelial cells. J Bacteriol 175: 4670-4680.
42. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. 2002. Multiple control of interleukin-8 gene expression. J Leukoc Biol 72: 847-855.
43. Eckmann L, Kagnoff MF, Fierer J. 1993. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun 61: 4569-4574.
44. Spehlmann ME, Dann SM, Hruz P, Hanson E, McCole DF, Eckmann L. 2009. CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen. J Immunol 183: 3332-3343. http://dx.doi.org/10.4049/jimmunol.0900600.
45. Ruchaud-Sparagano M-H, Maresca M, Kenny B. 2007. Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function. Cell Microbiol 9: 1909-1921. http://dx.doi.org/10.1111/j.1462-5822.2007.00923.x.
46. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 167: 1882-1885. http://dx.doi.org/10.4049/jimmunol.167.4.1882.
47. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Adarem A. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103. http://dx.doi.org/10.1038/35074106.
48. Naik S, Kelly EJ, Meijer L, Pettersson S, Sanderson IR. 2001. Absence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J Pediatr Gastroenterol Nutr 32: 449-453. http://dx.doi.org/10.1097/00005176-200104000-00011.
49. Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. 2003. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 170: 1406-1415. http://dx.doi.org/10.4049/jimmunol.170.3.1406.
50. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. 2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52: 847-853. http://dx.doi.org/10.1136/gut.52.6.847.
51. Jensen SR, Mirsepasi-Lauridsen HC, Thysen AH, Brynskov J, Krogfelt KA, Petersen AM, Pedersen AE, Brix S. 2015. Distinct inflammatory and cytopathic characteristics of Escherichia coli isolates from inflammatory bowel disease patients. Int J Med Microbiol 305: 925-936. http://dx.doi.org/10.1016/j.ijmm.2015.10.002.
52. Fournier BM, Parkos CA. 2012. The role of neutrophils during intestinal inflammation. Mucosal Immunol 5: 354-366. http://dx.doi.org/10.1038/mi.2012.24.
53. Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S. 2010. CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-κB, and MAPKs. J Immunol 185: 6214-6225. http://dx.doi.org/10.4049/jimmunol.0903843.
54. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, Nast CC, Lechago J, Xu R, Naiki Y, Soliman A, Arditi M, Abreu MT. 2005. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288: G1055-G1065. http://dx.doi.org/10.1152/ajpgi.00328.2004.
55. Shea-Donohue T, Thomas K, Cody MJ, Aiping Zhao Detolla LJ, Kopydlowski KM, Fukata M, Lira SA, Vogel SN. 2008. Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun 14: 117-124. http://dx.doi.org/10.1177/1753425908088724.
56. Bleich A, Sundberg JP, Smoczek A, Von Wasielewski R, de Buhr MF, Janus LM, Julga G, Ukena SN, Hedrich HJ, Gunzer F. 2008. Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int J Exp Pathol 89: 45-54.
57. Hafez M, Hayes K, Goldrick M, Warhurst G, Grencis R, Roberts IS. 2009. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect Immun 77: 2995-3003. http://dx.doi.org/10.1128/IAI.00040-09.
58. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. 2001. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167: 1609-1616. http://dx.doi.org/10.4049/jimmunol.167.3.1609.
59. Zhang C, Bai N, Chang A, Zhang Z, Yin J, Shen W, Tian Y, Xiang R, Liu C. 2013. ATF4 is directly recruited by TLR4 signaling and positively regulates TLR4-triggered cytokine production in human monocytes. Cell Mol Immunol 10: 84-94. http://dx.doi.org/10.1038/cmi.2012.57.
60. Robins-Browne RM, Hartland EL. 2002. Escherichia coli as a cause of diarrhea. J Gastroenterol Hepatol 17: 467-475. http://dx.doi.org/10.1046/j.1440-1746.2002.02769.x.
61. Jayamani E, Mylonakis E. 2014. Effector triggered manipulation of host immune response elicited by different pathotypes of Escherichia coli. Virulence 5: 733-739. http://dx.doi.org/10.4161/viru.29948.
62. Sanchez-Villamil J, Navarro-Garcia F. 2015. Role of virulence factors on host inflammatory response induced by diarrheagenic Escherichia coli pathotypes. Future Microbiol 10: 1009-1033. http://dx.doi.org/10.2217/fmb.15.17.
63. Ruchaud-Sparagano MH, Mühlen S, Dean P, Kenny B. 2011. The enteropathogenic E. coli (EPEC) Tir effector inhibits NF-κB activity by targeting TNFα receptor-associated factors. PLoS Pathog 7: e1002414. http://dx.doi.org/10.1371/journal.ppat.1002414.
64. Amiri KI, Richmond A. 2003. Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol 74: 1-36. http://dx.doi.org/10.1016/S0079-6603(03)01009-2.
65. Bambou J-C, Giraud A, Menard S, Begue B, Rakotobe S, Heyman M, Taddei F, Cerf-Bensussan N, Gaboriau-Routhiau V. 2004. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 279: 42984-42992. http://dx.doi.org/10.1074/jbc.M405410200.
66. Ramos HC, Rumbo M, Sirard JC. 2004. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 12: 509-517. http://dx.doi.org/10.1016/j.tim.2004.09.002.
67. Wehkamp J, Harder J, Wehkamp K, Meissner W, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Schröder JM, Stange EF. 2004. NF-κB-and AP-1-mediated induction of human β-defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72: 5750-5758. http://dx.doi.org/10.1128/IAI.72.10.5750-5758.2004.
68. Sharma R, Tesfay S, Tomson FL, Kanteti RP, Viswanathan VK, Hecht G. 2006. Balance of bacterial pro-and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 290: G685-G694. http://dx.doi.org/10.1152/ajpgi.00404.2005.
69. Zhou X, Girón JA, Torres AG, Crawford JA, Negrete E, Vogel SN, Kaper JB. 2003. Flagellin of enteropathogenic Escherichia coli stimulates interleukin-8 production in T84 cells. Infect Immun 71: 2120-2129. http://dx.doi.org/10.1128/IAI.71.4.2120-2129.2003.
70. Jessen DL, Osei-Owusu P, Toosky M, Roughead W, Bradley DS, Nilles ML. 2014. Type III secretion needle proteins induce cell signaling and cytokine secretion via Toll-like receptors. Infect Immun 82: 2300-2309. http://dx.doi.org/10.1128/IAI.01705-14.
71. Taganov KD, Boldin MP, Chang K-J, Baltimore D. 2006. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481-12486. http://dx.doi.org/10.1073/pnas.0605298103.